Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Preliminary Communication
10 May 2021

Shifting demographics and comorbidity burden in adult Chinese urban patients with chronic hepatitis B, 2013 and 2016

Authors: Jinlin Hou, Wendong Chen, Ying Han, Lei Wang, I-Heng Lee [email protected], Ling-I Hsu, Dongying Xie, Xueru Yin, Fengqin Hou, and Yida YangAuthor Info & Affiliations
Volume 10, Number 8
https://doi.org/10.2217/cer-2020-0080
PDFFormats

Abstract

Chronic hepatitis B demographics and comorbidity data are limited in China. Materials & methods: The China Health Insurance Association claims database from 2013 and 2016 was used to augment the existing data: the proportion of patients aged >45 years increased significantly from 40.3% in 2013 to 49% in 2016 (p < 0.001). Results: Significant increases in multiple comorbidities were observed, including hypertension (9.4–14.5%), hyperlipidemia (4.7–7.0%) and cardiovascular disease (5.7–10%; p < 0.001 for all comparisons). Increases were observed in renal impairment (8.8–10.0%; p < 0.001) and osteoporosis and/or pathologic nontraumatic bone fracture (3.8–7.3%; p < 0.001). Conclusion: Careful selection of treatment options and comorbidity monitoring should be considered when managing adult Chinese patients with chronic hepatitis B.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386(10003), 1546–1555 (2015).
PubMed
Google Scholar
2.
Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859), 2095–2128 (2012).
PubMed
Google Scholar
3.
World Health Organization. Up to 10 million people in China could die from chronic hepatitis by 2030--urgent action needed to bring an end to the ‘silent epidemic’. www.who.int/china/news/detail/26-07-2016-up-to-10-million-people-in-china-could-die-from-chronic-hepatitis-by-2030-urgent-action-needed-to-bring-an-end-to-the-silent-epidemic-. (26 July 2016)
Google Scholar
4.
Chen S, Li J, Wang D, Fung H, Wong LY, Zhao L. The hepatitis B epidemic in China should receive more attention. Lancet 391(10130), 1572 (2018).
PubMed
Google Scholar
5.
Zhang W, Ji Z, Wang L, Xiao D, Yan Y. A meta-analysis of HBsAg-positive rate among general Chinese populations aged 1–59 years. Infect. Dis. (Lond.) 47(12), 878–888 (2015).
PubMed
Google Scholar
6.
Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int. J. Infect. Dis. 16(2), e82–e88 (2012).
PubMed
Google Scholar
8.
Hou J, Wang G, Wang F et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J. Clin. Transl. Hepatol. 5(4), 297–318 (2017).
PubMed
Google Scholar
9.
Liu A, Le A, Zhang J et al. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin. Transl. Gastroenterol. 9(3), 141 (2018).
PubMed
Google Scholar
10.
Yang Y, Zhang J, Du F, Montgomery W, Li H, Flynn JA. Real world evidence in Mainland China: experience with the use of health care claims data. Value Health 17(7), A728 (2014).
PubMed
Google Scholar
11.
Zhao C, Wang C, Shen C, Wang Q. China’s achievements and challenges in improving health insurance coverage. Drug Discov. Ther. 12(1), 1–6 (2018).
PubMed
Google Scholar
12.
Zhang J, Ung COL, Wagner AK, Guan X, Shi L. Medication use during pregnancy in Mainland China: a cross-sectional analysis of a National Health Insurance database. Clin. Epidemiol. 11, 1057–1065 (2019).
PubMed
Google Scholar
13.
Yong M, Xianjun X, Jinghu L, Yunyun F. Effect of health insurance on direct hospitalisation costs for in-patients with ischaemic stroke in China. Aust. Health Rev. 42(1), 39–44 (2018).
PubMed
Google Scholar
14.
Wu P, Xu B, Shen A et al. The economic burden of medical treatment of children with asthma in China. BMC Pediatr. 20(1), 386 (2020).
PubMed
Google Scholar
15.
16.
17.
Wang H, Men P, Xiao Y et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis. BMC Infect. Dis. 19(1), 811 (2019).
PubMed
Google Scholar
18.
Sanai FM, Alghamdi H, Alswat KA et al. Greater prevalence of comorbidities with increasing age: cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi J. Gastroenterol. 25(3), 194–200 (2019).
PubMed
Google Scholar
19.
Tseng CH, Hsu YC, Ho HJ, Nguyen MH, Wu CY. Increasing age and non-liver comorbidities in patients with chronic hepatitis B in Taiwan: a nationwide population-based analysis. Dig. Dis. (2020) (Epub ahead of print).
Crossref
PubMed
Google Scholar
20.
Oh H, Jun DW, Lee IH et al. Increasing comorbidities in a South Korea insured population-based cohort of patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 52(2), 371–381 (2020).
PubMed
Google Scholar
21.
Wong GL, Yuen BW, Tse YK et al. Abstracts. Hepatol Int. 13, 1–266, Abstract no. 290 (2019).
PubMed
Google Scholar
22.
Jun DW, Oh H, Ahn HJ, Kim BO, Nguyen MH. Increased clinical and economic burden of chronic hepatitis B (CHB) patients compared to non-CHB from 2007 to 2016 in Korea. Presented at: Korean Association for the Study of the Liver (KASL). Haeundae-gu, Busan, South Korea(2019).
Google Scholar
23.
Hsu Y-C, Ho HJ, Nguen MH, Wu C-Y. Increasing age and non-liver comorbidities in chronic hepatitis B patients in Taiwan: a nationalwide population analysis. Presented at: Asian-Pacific Association for the Study of the Liver 2019 Annual Meeting. Manila, Philippines (2019). (Poster 631).
Google Scholar
24.
Yotsuyanagi H, Yatsuhashi H, Kurosaki M, Zur R, Sherman S, Nguyen MH. Increasing age and comorbidities in 13,639 adult patients with chronic hepatitis B (CHB) from 2011 to 2016 in Japan: results of a real-world analysis. Presented at: Asia-Pacific Association for the Study of the Liver Annual Conference 2018. New Delhi, India, (2018) Oral presentation no. O-HBV-36
Google Scholar
25.
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67(2), 370–398 (2017).
PubMed
Google Scholar
26.
Chen CH, Lin CL, Kao CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine (Baltimore) 94(50), e2276 (2015).
PubMed
Google Scholar
27.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1), 73–84 (2016).
PubMed
Google Scholar
28.
Lin CW, Huang XL, Liu HL, Wang Y. Interactions of hepatitis B virus infection with nonalcoholic fatty liver disease: possible mechanisms and clinical impact. Dig. Dis. Sci. 60(12), 3513–3524 (2015).
PubMed
Google Scholar
29.
Yang L, Shao J, Bian Y et al. Prevalence of Type 2 diabetes mellitus among inland residents in China (2000-2014): a meta-analysis. J. Diabetes Investig. 7(6), 845–852 (2016).
PubMed
Google Scholar
30.
Li Y, Teng D, Shi X et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 369, m997 (2020).
PubMed
Google Scholar
31.
Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 49(Suppl. 5), S174–S184 (2009).
PubMed
Google Scholar
|